Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.64 USD | +0.87% | +2.92% | +43.17% |
Business Summary
Number of employees: 557
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Autologous Tumor Infiltrating Lymphocytes
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30/16/30 |
Director of Finance/CFO | 51 | 14/20/14 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Chief Tech/Sci/R&D Officer | 51 | 18/19/18 | |
Igor Bilinsky
COO | Chief Operating Officer | 51 | 15/21/15 |
Merrill McPeak
BRD | Director/Board Member | 88 | 20/11/20 |
Sara Pellegrino
IRC | Investor Relations Contact | - | - |
Tracy Winton
HRO | Human Resources Officer | - | 01/20/01 |
Raj K. Puri
PRN | Corporate Officer/Principal | - | 01/22/01 |
Jim Ziegler
PRN | Corporate Officer/Principal | - | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20/11/20 |
Director/Board Member | 56 | 07/16/07 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15/18/15 |
Wendy Yarno
BRD | Director/Board Member | 68 | 18/23/18 |
Ryan Maynard
BRD | Director/Board Member | 54 | 16/15/16 |
Iain Dukes
CHM | Chairman | 65 | 01/16/01 |
Director/Board Member | 52 | 10/19/10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 2,842,158 | 0 | 0 | 92.70 % |
Stock B | 0 | 194 | 0 | 0 | |
Stock C | 1 | 278,847,679 | 258,503,652 ( 92.70 %) | 0 |
Company contact information
Iovance Biotherapeutics, Inc.
825 Industrial Road Suite 400
94070, San Carlos
+650 260 7120
http://www.iovance.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.17% | 3.25B | |
-20.45% | 10.82B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 383M | |
+13.32% | 332M |
- Stock Market
- Equities
- IOVA Stock
- Company Iovance Biotherapeutics, Inc.